Hepatitis C Virus Vaccine: Challenges and Prospects
The hepatitis C virus (HCV) causes both acute and chronic infection and continues to be a global problem despite advances in antiviral therapeutics. Current treatments fail to prevent reinfection and remain expensive, limiting their use to developed countries, and the asymptomatic nature of acute in...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/8/1/90 |
id |
doaj-fedb316bb3e04d3c8d452d19e1b9c2e4 |
---|---|
record_format |
Article |
spelling |
doaj-fedb316bb3e04d3c8d452d19e1b9c2e42020-11-25T02:18:24ZengMDPI AGVaccines2076-393X2020-02-01819010.3390/vaccines8010090vaccines8010090Hepatitis C Virus Vaccine: Challenges and ProspectsJoshua D. Duncan0Richard A. Urbanowicz1Alexander W. Tarr2Jonathan K. Ball3School of Life Sciences, The University of Nottingham, Nottingham NG7 2UH, UKSchool of Life Sciences, The University of Nottingham, Nottingham NG7 2UH, UKSchool of Life Sciences, The University of Nottingham, Nottingham NG7 2UH, UKSchool of Life Sciences, The University of Nottingham, Nottingham NG7 2UH, UKThe hepatitis C virus (HCV) causes both acute and chronic infection and continues to be a global problem despite advances in antiviral therapeutics. Current treatments fail to prevent reinfection and remain expensive, limiting their use to developed countries, and the asymptomatic nature of acute infection can result in individuals not receiving treatment and unknowingly spreading HCV. A prophylactic vaccine is therefore needed to control this virus. Thirty years since the discovery of HCV, there have been major gains in understanding the molecular biology and elucidating the immunological mechanisms that underpin spontaneous viral clearance, aiding rational vaccine design. This review discusses the challenges facing HCV vaccine design and the most recent and promising candidates being investigated.https://www.mdpi.com/2076-393X/8/1/90hepatitis c virusvaccinesneutralising antibodiesanimal modelsimmune responses |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Joshua D. Duncan Richard A. Urbanowicz Alexander W. Tarr Jonathan K. Ball |
spellingShingle |
Joshua D. Duncan Richard A. Urbanowicz Alexander W. Tarr Jonathan K. Ball Hepatitis C Virus Vaccine: Challenges and Prospects Vaccines hepatitis c virus vaccines neutralising antibodies animal models immune responses |
author_facet |
Joshua D. Duncan Richard A. Urbanowicz Alexander W. Tarr Jonathan K. Ball |
author_sort |
Joshua D. Duncan |
title |
Hepatitis C Virus Vaccine: Challenges and Prospects |
title_short |
Hepatitis C Virus Vaccine: Challenges and Prospects |
title_full |
Hepatitis C Virus Vaccine: Challenges and Prospects |
title_fullStr |
Hepatitis C Virus Vaccine: Challenges and Prospects |
title_full_unstemmed |
Hepatitis C Virus Vaccine: Challenges and Prospects |
title_sort |
hepatitis c virus vaccine: challenges and prospects |
publisher |
MDPI AG |
series |
Vaccines |
issn |
2076-393X |
publishDate |
2020-02-01 |
description |
The hepatitis C virus (HCV) causes both acute and chronic infection and continues to be a global problem despite advances in antiviral therapeutics. Current treatments fail to prevent reinfection and remain expensive, limiting their use to developed countries, and the asymptomatic nature of acute infection can result in individuals not receiving treatment and unknowingly spreading HCV. A prophylactic vaccine is therefore needed to control this virus. Thirty years since the discovery of HCV, there have been major gains in understanding the molecular biology and elucidating the immunological mechanisms that underpin spontaneous viral clearance, aiding rational vaccine design. This review discusses the challenges facing HCV vaccine design and the most recent and promising candidates being investigated. |
topic |
hepatitis c virus vaccines neutralising antibodies animal models immune responses |
url |
https://www.mdpi.com/2076-393X/8/1/90 |
work_keys_str_mv |
AT joshuadduncan hepatitiscvirusvaccinechallengesandprospects AT richardaurbanowicz hepatitiscvirusvaccinechallengesandprospects AT alexanderwtarr hepatitiscvirusvaccinechallengesandprospects AT jonathankball hepatitiscvirusvaccinechallengesandprospects |
_version_ |
1724882386070536192 |